New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health ...

These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, ...

A new study found a link between new popular GIP/GLP-1 receptor agonists and a reduced rate of overdose or intoxication in ...

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies ...

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

Weight-loss and diabetes drugs like Ozempic and Mounjaro could be used to treat drug and alcohol addiction in the future — ...

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...